ELUT Stock Overview
A commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Elutia Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.84 |
| 52 Week High | US$5.24 |
| 52 Week Low | US$1.97 |
| Beta | 0.86 |
| 1 Month Change | 17.48% |
| 3 Month Change | 25.71% |
| 1 Year Change | 137.25% |
| 3 Year Change | -27.44% |
| 5 Year Change | n/a |
| Change since IPO | -66.62% |
Recent News & Updates
Recent updates
Elutia Inc. (NASDAQ:ELUT) Held Back By Insufficient Growth Even After Shares Climb 26%
Nov 20
Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Jun 28News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat
Mar 10Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues
Feb 21Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding
Apr 17Aziyo Biologics appoints Williams as Chief Scientific Officer
Aug 26Aziyo Biologics names co-founder C. Randal Mills as permanent CEO
Aug 10Shareholder Returns
| ELUT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 16.9% | -3.6% | -2.4% |
| 1Y | 137.3% | -2.7% | 23.3% |
Return vs Industry: ELUT exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: ELUT exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| ELUT volatility | |
|---|---|
| ELUT Average Weekly Movement | 14.9% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ELUT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ELUT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 54 | Randy Mills | elutia.com |
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women’s Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
Elutia Inc. Fundamentals Summary
| ELUT fundamental statistics | |
|---|---|
| Market cap | US$167.28m |
| Earnings (TTM) | -US$60.29m |
| Revenue (TTM) | US$24.78m |
6.8x
P/S Ratio-2.8x
P/E RatioIs ELUT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELUT income statement (TTM) | |
|---|---|
| Revenue | US$24.78m |
| Cost of Revenue | US$14.27m |
| Gross Profit | US$10.51m |
| Other Expenses | US$70.80m |
| Earnings | -US$60.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.74 |
| Gross Margin | 42.41% |
| Net Profit Margin | -243.28% |
| Debt/Equity Ratio | -56.3% |
How did ELUT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:53 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Elutia Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Frank Takkinen | Lake Street Capital Markets, LLC |